The continued challenge of staphylococcus aureus in the surgical patient

American Surgeon

Volumn 79, Issue 1, 2013, Pages 1-10

  Fry, Donald E ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CEFAZOLIN; CEFTAROLINE; CEPHALOSPORIN; CLINDAMYCIN; COAGULASE; COTRIMOXAZOLE; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; EXOTOXIN; LINEZOLID; METICILLIN; MINOCYCLINE; NATURAL PRODUCT; PANTON VALENTINE LEUKOCIDIN; PLACEBO; PSEUDOMONIC ACID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL VIRULENCE; CELL STRUCTURE; DISEASE SURVEILLANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INFECTION RATE; KIDNEY DISEASE; LEUKOPENIA; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PREOPERATIVE EVALUATION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; SURGICAL INFECTION; SURGICAL PATIENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PREOPERATIVE CARE;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREOPERATIVE CARE; STAPHYLOCOCCAL INFECTIONS; SURGICAL WOUND INFECTION; VANCOMYCIN RESISTANCE; VIRULENCE FACTORS;

MLCS; MLOWN;

EID: 84875057070     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Fry DE, Barie PS. The changing face of Staphylococcus aureus: a continuing surgical challenge. Surg Infect (Larchmt) 2011;12:191-203.
2. Kirby WM. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science 1944;99: 452-3.
3. Ross G, Rodriguez W, Controni G, et al. Staphylococcal susceptibility to penicillin G: the changing pattern among community strains. JAMA 1974;229:1075-7.
4. Jevons MP, Rolinson GN, Knox R. 'Celbenin'-resistant staphylococci. BMJ 1961;1:124-6.
5. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993;25:97-108.
6. Herald BC, Immergluck LC, Maranan MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-8.
7. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139.
8. Sánchez Garćia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4.
9. Hageman JC, Patel JB, Carey RC, et al. Investigation and control of vancomycin-intermediate and -resistant Staphylococcus aureus. A guide for health departments and infection control personnel. Atlanta, GA: Centers for Disease Control and Prevention; 2006. Available at: www.cdc.gov/ncidod/dhqp/ar-visavrsa- prevention.html. Accessed: October 22, 2012.
10. Pietrocola G, Arciola CR, Rindi S, et al. Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus. Int J Artif Organs 2011;34:799-810.
11. Patti JM, Allen BL, McGavin MJ, et al. MSCRAMMmediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994;48:585-617.
12. Roche FM, Downer R, Keane F, et al. The N terminal A domain of fibronectin-binding proteins A and B promotes adhesion of Staphylococcus aureus to elastin. J Biol Chem 2004;279: 38433-40.
13. Switalski LM, Patti JM, Butcher W, et al. A collagen receptor in Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage. Mol Microbiol 1993; 7:99-107.
14. Hartlieb J, Kohler N, Dickinson RB, et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 2000;96:2149-56.
15. Tung H, Buss B, Hellman U, et al. A bone sialoprotein binding protein from Staphylococcus aureus: a member of the Sdr family. Biochem J 2000;345:611-9.
16. Chavakis T, Wiechmann K, Preissner KT, Herrmann M. Staphylococcus aureus interacts with the endothelium: the role of bacterial 'secretable expanded repertoire adhesive molecules' (SERAM) in disturbing host defense systems. Thromb Haemost 2005;94:278-85.
17. Panton PN, Valentine FCO. Staphylococcal toxin. Lancet 1932;1:506-8.
18. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 2010;64:143-62.
19. Archer NK, Mazaitis MJ, Costerton JW, et al. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2011;2:445-59.
20. Archer NK, Mazaitis MJ, Costerton JW, et al. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2011;2:445-59.
21. Lindsay J, Holden M. Staphylococcus aureus: superbug, super genome? Trends Microbiol 2004;12:378-85.
22. Malachowa N, DeLeo FR. Mobile genetic elements of Staphylococcus aureus. Cell Mol Life Sci 2010;67:3057-71.
23. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009;7: 629-41.
24. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006;119(suppl 6A):S3-10.
25. Brown MH, Skurray RA. Staphylococcal multidrug efflux protein QacA. J Mol Microbiol Biotechnol 2001;3:163-70.
26. Hackbarth CJ, Chambers HF. BlaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1993;37: 1144-9.
27. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
28. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29:1171-7.
29. Stryjewski ME, Szczech LA, Benjamin DK Jr. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007;44:190-6.
30. Hanssen AM, Ericson Sollid JU. SCCmec in staphylococci: genes on the move. FEMS Immunol Med Microbiol 2006;46:8-20.
31. David MZ, Daum RS. Community-associated methicillinresistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010;23: 616-87.
32. Centers for Disease Control and Prevention. CDC Reminds Clinical Laboratories and Healthcare Infection Preventionists of their Role in the Search and Containment of Vancomycin-resistant Staphylococcus aureus (VRSA), May 2010. Available at: www.bt. cdc.gov/coca/reminders/2010/2010may06.asp. Accessed: October 22, 2012.
33. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011;1241:48-70.
34. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
35. Wunderink RG, Cammarata SK, Oliphant T, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92.
36. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012;56:603-12.
37. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009;23:99-131.
38. Tally FP, DeBruin MF. Development of daptomycin for Gram positive infections. J Antimicrob Chemother 2000;46:523-6.
39. Nailor MD, Sobel JD. Antibiotics for Gram positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am 2009;23:965-82.
40. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:516-21.
41. Rose W, Rybak M. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006;26:1099-110.
42. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of two double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl 5): S341-53.
43. Towfigh S, Pasternak J, Poirier A, et al. A multicenter, openlabel, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010;16:1274-81.
44. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008;60:421-7.
45. Cai Y, Wang R, Liang B, et al. Systematic review and metaanalysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55: 1162-72.
46. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 2010;30:80-94.
47. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7.
48. Roecker AM, Pope SD. Dalbavancin: a lipoglycopeptide antibacterial for Gram-positive infections. Expert Opin Pharmacother 2008;9:1745-54.
49. Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents 2010;36:401-7.
50. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against Gram positive pathogens. Pharmacotherapy 2010;30:375-89.
51. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS I: the first phase III, randomized, double-blind, study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(suppl 4):iv41-51.
52. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65(suppl 4):iv53-65.
53. Dauner DG, Nelson RE, Taketa DC. Ceftobiprole: a novel, broad-spectrum cephalosporin with activity against methicillinresistant Staphylococcus aureus. Am J Health Syst Pharm 2010;67: 983-93.
54. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003;37:1257-60.
55. Bratzler DW, Houck PM; Surgical Infection Prevention Guideline Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 2005;189:395-404.
56. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999;20:247-78.
57. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002;123:326-32.
58. Smith EB, Wynne R, Joshi A, et al. Is it time to include vancomycin for routine perioperative antibiotic prophylaxis in total joint arthroplasty patients? J Arthroplasty 2012;27(suppl):55-60.
59. Sewick A, Makani A, Wu C, et al. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res 2012 Jan 31 [Epub ahead of print].
60. Gorwitz RJ, Druszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008;197: 1226-34.
61. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-5.
62. Edwards AM, Massey RC, Clarke SR. Molecular mechanisms of Staphylococcus aureus nasopharyngeal colonization. Mol Oral Microbiol 2012;27:1-10.
63. McConeghyKW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009;29:263-80.
64. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009;49:935-41.
65. Bode LGM, Kluytmans JAHW, Wertheim HFL, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010;362:9-12.
66. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopaedic surgery: the effect of mupirocin ointment in a double-blind, randomized placebocontrolled study. Clin Infect Dis 2002;35:353-8.
67. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871-7.
68. Suzuki Y, Kamigaki T, Fujino Y, et al. Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery. Br J Surg 2003;90:1072-5.
69. Konvalinka A, Errett L, Fong JW. Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery. J Hosp Infect 2006;64:162-8.
70. Simor AE. Staphylococcal decolonization: an effective strategy for prevention of infection? Lancet Infect Dis 2011;11:952-62.
71. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012;54:560-7.
72. Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009;23:153-71.
73. Long J, Zaborina O, Holbrook C, et al. Depletion of intestinal phosphate after operative injury activates the virulence of P aeruginosa causing lethal gut-derived sepsis. Surgery 2008;144: 189-97.